Rodriguez W J, Khan W H, Sait T, Chhabra O P, Guarinello A, Smith A W, Ahmad S
Department of Infectious Diseases, Children's Hospital, National Medical Center, Washington, DC 20010.
J Int Med Res. 1990;18 Suppl 4:78D-84D.
A comparative study of sultamicillin (an orally active dimer of sulbactam and ampicillin) and amoxycillin for the treatment of acute otitis media was carried out in 86 children with acute otitis media. After 10 days' treatment, of those with traditional middle ear pathogens, 35/36 (97%) 50 mg/kg.day or 500 mg/day sultamicillin-treated children were cured with eight relapses after a further 18 days without treatment compared with 12/13 (92%) 40 mg/kg.day or 250 mg/day amoxycillin-treated children and three subsequent relapses. All six beta-lactamase-producing pathogens were in the sultamicillin treatment group: four were Haemophilus influenzae/H. parainfluenzae that were resistant to amoxycillin, and all were cured although two then relapsed. No significant clinical or laboratory side-effects were noted in either amoxycillin- or sultamicillin-treated patients. It is concluded that sultamicillin was comparable to amoxycillin in the treatment of acute otitis media.
对86例急性中耳炎患儿进行了舒他西林(舒巴坦和氨苄西林的口服活性二聚体)与阿莫西林治疗急性中耳炎的对比研究。治疗10天后,对于感染传统中耳病原体的患儿,接受50mg/kg·天或500mg/天舒他西林治疗的36例患儿中有35例(97%)治愈,在未进一步治疗的18天后有8例复发;相比之下,接受40mg/kg·天或250mg/天阿莫西林治疗的13例患儿中有12例(92%)治愈,随后有3例复发。所有6例产β-内酰胺酶病原体均在舒他西林治疗组:4例为对阿莫西林耐药的流感嗜血杆菌/副流感嗜血杆菌,尽管其中2例随后复发,但均治愈。阿莫西林或舒他西林治疗的患者均未出现明显的临床或实验室副作用。结论是,舒他西林在治疗急性中耳炎方面与阿莫西林相当。